Short Interest in Exicure, Inc. (NASDAQ:XCUR) Drops By 78.8%

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 107,470 shares, a decline of 78.8% from the July 15th total of 506,729 shares. Based on an average trading volume of 138,757 shares, the short-interest ratio is currently 0.8 days. Currently, 3.6% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Exicure Price Performance

Shares of XCUR opened at $1.25 on Friday. The company’s fifty day moving average price is $1.96 and its 200-day moving average price is $3.14. Exicure has a 1-year low of $1.18 and a 1-year high of $9.48. The firm has a market capitalization of $7.96 million, a PE ratio of -0.81 and a beta of 3.65.

Exicure (NASDAQ:XCUR) last issued its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.42.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.